文献速递妇科产科

Xenform牛真皮基质经阴道盆腔器官脱垂修复的MAUDE报告分析

Characterizing MAUDE Reports for Xenform Bovine Dermal Matrix in Transvaginal Pelvic Organ Prolapse Repair: A Mixed-Methods Descriptive Analysis.
PubMed 文献 · J Minim Invasive Gynecol · 2026-07-29

本研究混合方法分析2010-2025年FDA MAUDE数据库中1209份Xenform相关报告,发现81.7%为律师提交,仅1.1%为高度可能器械相关事件。报告量在2013年FDA监管与诉讼活动期达峰,提示报告模式反映医疗法律背景而非材料特异性安全信号。

要点

  • MAUDE报告中81.7%为律师提交,80.8%缺乏足够临床细节。
  • 仅1.1%报告为高度可能器械相关事件,包括脓肿需取出移植物等。
  • 报告量2013年达峰与FDA监管及诉讼活动重合,非材料安全信号。

核心结论

  • 少数MAUDE报告包含足够细节将不良事件归因于Xenform。
  • 报告量峰值与FDA监管和诉讼活动重合,提示报告模式反映医疗法律背景而非材料特异性安全信号。
  • 缺乏详细报告并非安全性证据,而是被动监测的结构性局限。

研究设计与样本

  • 混合方法描述性研究,结合MAUDE数据库系统综述与前瞻性临床证据及FDA监管摘要的叙述性综述。
  • 纳入2010年1月至2025年12月提交的引用Xenform的MAUDE报告,共1209份。

主要发现

  • 律师提交占81.7%(n=1209),80.8%(n=1196)缺乏足够临床细节。
  • 仅16份报告(1.1%)为高度可能器械相关事件,包括术后脓肿需取出移植物(n=3)、需再手术的盆腔痛(n=6)、阴道缝线裂开(n=7)。

临床怎么用

  • 解读MAUDE报告时需考虑提交来源和细节缺失对归因的影响。
  • Xenform相关证据支持材料类别权衡而非与合成网片等同的风险特征。
  • 产品撤市缩小了复发或复杂POP患者的手术选择。

局限性

  • 被动监测数据库存在结构性局限,报告缺乏详细临床信息。
  • 报告模式可能受医疗法律背景影响,无法确立因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: Following the 2019 Food and Drug Administration (FDA) order to cease sales of transvaginal pelvic organ prolapse (POP) repair devices, questions persist regarding adverse event attribution for biologic grafts. We aimed to characterize FDA Manufacturer and User Facility Device Experience (MAUDE) reports referencing Xenform for transvaginal POP repair and contextualize findings with prospective clinical evidence and FDA postmarket ("522") data. DESIGN: Mixed-methods descriptive study combining systematic MAUDE database review with narrative review of prospective clinical evidence and FDA regulatory summaries. SETTING: FDA MAUDE publicly available surveillance database. PATIENTS: MAUDE reports referencing Xenform submitted between January 2010 and December 2025. INTERVENTIONS: Xenform bovine dermal matrix for transvaginal POP repair. MEASUREMENTS AND MAIN RESULTS: Attorney submissions comprised 81.7% of reports (n = 1209); 80.8% (n = 1196) lacked sufficient clinical detail. Only 16 reports (1.1%) were classified as high-likelihood device-related events, including postoperative abscess requiring graft explant (n = 3), pelvic pain requiring reoperation (n = 6), and vaginal suture-line separation (n = 7). CONCLUSION: Few MAUDE narratives contained sufficient detail to implicate Xenform in a device-attributed adverse event. Report volume peaked in 2013 coincident with FDA regulatory activity and mesh litigation, suggesting Xenform reporting patterns may have reflected the broader medicolegal context rather than a material-specific safety signal. The absence of detailed reporting is not evidence of safety, but reflects structural limitations of passive surveillance. Available evidence supports material-class trade-offs rather than a risk profile equivalent to synthetic mesh. The withdrawal has narrowed surgical options for patients with recurrent or complex POP. Prospective, long-term data on biologic graft safety remain a priority to inform future regulatory evaluation.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Corn M, Elliott CS, Sokol ER, et al. Characterizing MAUDE Reports for Xenform Bovine Dermal Matrix in Transvaginal Pelvic Organ Prolapse Repair: A Mixed-Methods Descriptive Analysis. J Minim Invasive Gynecol. 2026. PMID: 42526833. doi:10.1016/j.jmig.2026.07.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。